Skip to main content
General

Where J&J $2.2B Settlement Fits Among Biggest?

By November 5, 2013No Comments

Johnson & Johnson’s (JNJ) agreement to pay $2.2 billion for off-label marketing of the anti-psychotic drug Risperdal brings to more than $11 billion the amount of penalties pharmaceutical makers have been assessed for getting doctors to prescribe drugs for purposes other than approved by the FDA.

Known, as off-label marketing, the practice has helped boost drug sales over the years but frustrated regulators and law enforcement officials.

J&J’s settlement is huge, but not the largest. Here’s a not-entirely-comprehensive list, onto which J&J would become No. 2.

1. Pfizer (PFE) – $2.3 billion, 2009
2. Abbott (ABT) – $1.5 billion, 2012,
3. Eli Lilly (LLY) – $1.415 billion, 2009
4. Merck Sharp & Dohme – $950 million, 2011
5. TAP Pharmaceuticals – $875 million, 2001
6. Serono, S.A. – $704 million, 2005
7. Purdue Pharma – $634 million, 2007
8. Allergan (AGN) – $600 million, 2010
9. AstraZeneca (AZN) – $520 million, 2010
10. Bristol-Myers Squibb (BMY) – $515 million, 2007

Leave a Reply